TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:02
Reneo Pharmaceuticals Inc. ( RPHM ) https://reneopharma.com
1.65USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-69.56%
RPHM
SPY
32.74%
RPHM
0.00%
SPY
92.93%
RPHM
0.00%
SPY
224.41%
RPHM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
55.78
-56.96
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.85
0.00
0.49
-112.78
0.00
0.72
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-688.50
-76.69
0.00
Other Earnings and Cash Flow Stats:
Reneo Pharmaceuticals Inc. ( RPHM ) Net Income TTM ($MM) is -58.10
Reneo Pharmaceuticals Inc. ( RPHM ) Operating Income TTM ($MM) is -65.41
Reneo Pharmaceuticals Inc. ( RPHM ) Owners' Earnings Annual ($MM) is 0.00
Reneo Pharmaceuticals Inc. ( RPHM ) Current Price to Owners' Earnings ratio is 0.00
Reneo Pharmaceuticals Inc. ( RPHM ) EBITDA TTM ($MM) is -65.27
Reneo Pharmaceuticals Inc. ( RPHM ) EBITDA Margin is 0.00%
Capital Allocation:
Reneo Pharmaceuticals Inc. ( RPHM ) has paid 0.00 dividends per share and bought back -9.31152 million shares in the past 12 months
Reneo Pharmaceuticals Inc. ( RPHM ) has reduced its debt by 0.326 million USD in the last 12 months
Capital Structure:
Reneo Pharmaceuticals Inc. ( RPHM ) Interest-bearing Debt ($MM) as of last quarter is 1
Reneo Pharmaceuticals Inc. ( RPHM ) Annual Working Capital Investments ($MM) are 18
Reneo Pharmaceuticals Inc. ( RPHM ) Book Value ($MM) as of last quarter is 114
Reneo Pharmaceuticals Inc. ( RPHM ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Reneo Pharmaceuticals Inc. ( RPHM ) has 11 million in cash on hand as of last quarter
Reneo Pharmaceuticals Inc. ( RPHM ) has 13 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Reneo Pharmaceuticals Inc. ( RPHM ) has 33 common shares outstanding as of last quarter
Reneo Pharmaceuticals Inc. ( RPHM ) has 0 million USD of preferred stock value
Academic Scores:
Reneo Pharmaceuticals Inc. ( RPHM ) Altman Z-Score is -0.82 as of last quarter
Reneo Pharmaceuticals Inc. ( RPHM ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Reneo Pharmaceuticals Inc. ( RPHM ) largest shareholder is Millennium Management LLC owning 122685 shares at 0.20 ($MM) value
Ashley Hall(an insider) Sold 15625 shares of Reneo Pharmaceuticals Inc. ( RPHM ) for the amount of $98125.00 on 2023-08-28
2.07% of Reneo Pharmaceuticals Inc. ( RPHM ) is held by insiders, and 88.38% is held by institutions
Reneo Pharmaceuticals Inc. ( RPHM ) went public on 2021-04-08
Other Reneo Pharmaceuticals Inc. ( RPHM ) financial metrics:
FCF:-54.69
Unlevered Free Cash Flow:-95.43
EPS:-2.27
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-66.80
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Reneo Pharmaceuticals Inc. ( RPHM ) :
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.